Why the study?
Patients with hepatitis B-related cirrhosis complicated with thrombocytopenia have a higher risk of bleeding, which may lead to higher mortality.
Does recombinant human thrombopoietin (rhTPO) improve platelet counts and reduce bleeding in patients with hepatitis B-related compensated liver cirrhosis complicated with severe thrombocytopenia?
Population
Patients with hepatitis B-related compensated liver cirrhosis complicated with severe thrombocytopenia
Comparison
rhTPO vs prednisone vs prednisone plus rhTPO vs no treatment
Design
Multicentre real-world observational study
Authors
Loading...
rhTPO may raise platelets in HBV-cirrhosis thrombocytopenia; leaves open need for RCTs before practice change.
Does recombinant human thrombopoietin (rhTPO) improve platelet counts and reduce bleeding in patients with hepatitis B-related compensated liver cirrhosis complicated with severe thrombocytopenia?
Recombinant human thrombopoietin, alone or with prednisone, effectively increases platelet counts and reduces bleeding risk in patients with hepatitis B-related cirrhosis and severe thrombocytopenia, particularly in those without splenomegaly.
Feng et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: